Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

Table 1

Demographic and clinical data (on PD medication).

	Nondepressed Parkinson’s; patients; ; (SD)	Depressed Parkinson’s; patients; ; (SD)	value
Age y, mean (SD)	68.4 (8.2)	55.2 (7.0)	0.0002
Education	16.0 (3.1)	15.6 (2.3)	NS
Men/women	11/7	7/3	NS
Months since diagnosis	55.7 (39.9)	43.6 (44.0)	NS
DRS-scaled	11.0 (2.5)	12.0 (2.5)	NS
NART-R-FSIQ	107.5 (7.8)	99.1 (11.8)	0.0321
GDS-15	1.9 (1.9)	6.2 (3.4)	0.0002
Hamilton Depression Scale	4.6 (3.7)	15.0 (4.6)	<0.0001
UPDRS-Motor	16.6 (6.3)	15.0 (6.2)	NS
UPDRS-Tremor	1.1 (1.7)	0.9 (1.2)	NS
Schwab-England ADL	89.2 (11.5)	84.0 (13.5)	NS
Levodopa equivalent daily dose	513.1 (377.7)	525.0 (430.9)	NS
% on DA agonists	61.1	60.0	NS

Note:
DRS: Mattis Dementia Rating Scale.
NART-R-FSIQ: National Adult Reading Test-Revised, Estimated Full-Scale IQ.
GDS-15: Geriatric Depression Scale-15-Item Version.
UPDRS: Unified Parkinson’s Disease Rating Scale.
-test.
test.